#United States #New York #Securities Fraud #Rosen Law Firm #Unicycive Therapeutics

Investors Get Opportunity to Lead Class Action Against Unicycive Therapeutics Securities Fraud

Investors Have Chance to Lead Class Action Against Unicycive Therapeutics

In a significant development for investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY), those who purchased securities from December 29, 2025, to June 29, 2026, are reminded of a crucial deadline to potentially lead a class action lawsuit. This announcement was made by Rosen Law Firm, known globally for its advocacy of investor rights. The firm is urging affected investors to take action as the deadline to become the lead plaintiff is set for November 2, 2026.

What Does This Mean for Investors?

If you bought Unicycive securities during the specified class period, you may qualify for compensation, which will come at no upfront cost to you due to a contingency fee agreement. Those interested in participating can find further details here or can reach out to Phillip Kim, Esq. directly to get personalized assistance.

Accusations Underlying the Class Action

The class action filed against Unicycive alleges that the company made materially false and misleading statements about its operations and compliance. Key accusations include:
1. Lack of Vendor Inspection: It was claimed that Unicycive did not adequately inspect its third-party manufacturing vendor’s facility or ensure its compliance with good manufacturing practices.
2. Unrevealed Risks: There was a failure to disclose risks related to potential additional scrutiny from the U.S. Food and Drug Administration (FDA) concerning the vendor's practices.
3. Misleading Company Statements: Due to these factors, statements made by the defendants about Unicycive’s financial health and business outlook were deemed misleading.

When factual details came to light, this resulted in serious financial repercussions for investors, prompting the need for this lawsuit.

The Importance of Choosing the Right Legal Representation

In light of the complexity involved in securities litigation, Rosen Law Firm encourages investors to carefully select their legal counsel. A significant number of law firms typically function merely as intermediaries rather than actively engaging in litigation. Rosen Law Firm differentiates itself through its extensive experience and proven track record, notably achieving the largest securities class action settlement to date against a Chinese company. Furthermore, they have consistently ranked among the top firms for securities class action settlements.

Next Steps for Interested Investors

Should you wish to engage in this class action and possibly step up as the lead plaintiff, it is essential to act promptly before the November deadline. The Rosen Law Firm emphasizes that investors don’t have to choose to participate as lead plaintiff, but doing so can allow you to influence proceedings directly.

For those who prefer to remain passive participants, it’s important to understand that this will not affect your potential recovery in any future settlements.

Stay Updated

Investors are encouraged to stay updated on this proceeding by following the Rosen Law Firm on their social media channels, including LinkedIn, Twitter, and Facebook. Staying informed can provide additional context and updates on the case's progress.

As this situation unfolds, affected investors have a chance to seek justice and potentially recoup losses sustained due to allegedly deceptive practices by Unicycive Therapeutics. Time is of the essence, and quick action may yield the best results.

For more information on the class action lawsuit, you can contact: